ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Recurrence
Cancer
Hematologic Cancer
Non-Hodgkin Lymphoma
Lymphoma
Leukemia

Multiple Myeloma trials near Pittsburgh, PA, USA:

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

(BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Alnuctamab
Drug: Iberdomide

Phase 1

Juno Therapeutics

Pittsburgh, Pennsylvania, United States and 18 other locations

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A study designed tocompare progression-free survival (PFS) in participants with t(11;14)-positive MM treated with venetoclax in combination with dexa...

Active, not recruiting
Multiple Myeloma
Drug: Pomalidomide
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Pittsburgh, Pennsylvania, United States and 182 other locations

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5)

Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as in...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 136 other locations

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2)

The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to ide...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 26 other locations

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MonumenTAL-2)

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to id...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Carfilzomib

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 30 other locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

Phase 3

Pfizer
Pfizer

Pittsburgh, Pennsylvania, United States and 273 other locations

Locations recently updated

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple...

Enrolling
Relapsed or Refractory Multiple Myeloma (RRMM)
Drug: BMS-986393
Drug: Daratumumab

Phase 3

Juno Therapeutics

Pittsburgh, Pennsylvania, United States and 138 other locations

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

maintenance to lenalidomide maintenance therapy after autologous stem cell transplantation (ASCT) in participants with newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Pittsburgh, Pennsylvania, United States and 289 other locations

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (CARTITUDE-2)

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Bortezomib

Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Pittsburgh, Pennsylvania, United States and 47 other locations

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the ...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Teclistamab

Phase 3

European Myeloma Network B.V.

Pittsburgh, Pennsylvania, United States and 214 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems